title: FDA panel advises easing restrictions on rosiglitazone.
authors.forename: Miriam E
authors.initials: ME
authors.lastname: Tucker
mesh_terms: D003920:Diabetes Mellitus / Q000188:drug therapy; D004335:Drug and Narcotic Control / Q000379:methods*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D009203:Myocardial Infarction / Q000139:chemically induced / Q000517:prevention & control; D011358:Product Surveillance, Postmarketing; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000009:adverse effects; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone